Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE versus MINOXIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE versus MINOXIDIL.
HYDRALAZINE HYDROCHLORIDE vs MINOXIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vasodilation of arterioles by direct relaxation of vascular smooth muscle, likely involving interference with calcium movement.
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. In hair follicles, it promotes hair growth by increasing blood flow and prolonging the anagen phase, possibly through stimulation of prostaglandin synthesis.
Oral: Initiate with 10 mg 4 times daily for 2-4 days, then increase to 25 mg 4 times daily for the remainder of the week, then titrate to 50 mg 4 times daily. Maximum daily dose: 300 mg. Intravenous: 5-20 mg IV bolus, may repeat every 20-30 minutes as needed, or continuous IV infusion 0.5-10 mg/hour.
Oral: 5-40 mg/day in 1-2 divided doses, starting at 5 mg/day and titrating upward; Topical: 1 mL of 2% or 5% solution twice daily.
None Documented
None Documented
Clinical Note
moderateMinoxidil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid."
Clinical Note
moderateMinoxidil + Furosemide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide."
Clinical Note
moderateMinoxidil + Bumetanide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide."
Clinical Note
moderateMinoxidil + Travoprost
The terminal elimination half-life of hydralazine is approximately 2–4 hours in patients with normal renal function, but it is prolonged in renal impairment (up to 7–16 hours). The antihypertensive effect often lasts longer than the half-life due to persistent binding to arteriolar receptors.
Terminal elimination half-life: 4.2 hours; clinical context: may be prolonged in renal impairment (up to 18 hours), requiring dose adjustment.
Hydralazine is primarily metabolized in the liver via N-acetylation (polymorphic) and hydroxylation. Less than 10% of the dose is excreted unchanged in urine. The major metabolites are hydralazine pyruvic acid hydrazone and other conjugates, which are excreted renally. Fecal elimination is negligible.
Renal: 90% as unchanged drug and metabolites; fecal: 10% via bile.
Category A/B
Category A/B
Vasodilator
Vasodilator / Hair Growth Stimulant
"Minoxidil may increase the hypotensive activities of Travoprost."